Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
- Your cancer can be measured on scans or tests
- You are generally well enough to carry out daily activities with little or no limitation (confirm with trial site)
- (Part 1 of the trial): Your cancer has continued to grow or come back after receiving standard treatments
- (Part 2 of the trial): You have received no more than 2 previous treatment courses for your advanced cancer
- Any side effects from your previous cancer treatments have mostly or fully cleared up
- You are willing to provide a sample of your tumor tissue before treatment begins, if medically possible
Who may not be able to join:
- You have previously been treated with certain targeted drug therapies known as antibody-drug conjugates that contain a specific type of ingredient called a camptothecin payload — for example, sacituzumab govitecan or trastuzumab deruxtecan
- You are currently experiencing significant loss of appetite, nausea, vomiting, or signs of a blockage in your bowel (confirm with trial site for exact details)
- You have certain lung conditions or lung problems that meet the trial's exclusion rules (confirm with trial site for exact details)
- You have certain other health or test result abnormalities that the trial rules do not allow (confirm with trial site for exact details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation; Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy; Part 1: Recommended Monotherapy Dose for Expansion; Part 2: Recommended Phase 2 Dose
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.